EyePoint Pharmaceuticals, Inc. (EYPT)
Stock Price Chart
Key Info
| Market Cap | 61.75M |
| Revenue (ttm) | 35.94M |
| Net Income (ttm) | -40.34M |
| Shares Out | 143.52M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 24 |
| Last Price | $0.430 |
| Previous Close | $0.430 |
| Change ($) | 0.000 |
| Change (%) | 0.07% |
| Day's Open | 0.421 |
| Day's Range | 0.415 - 0.432 |
| Day's Volume | 629,360 |
| 52-Week Range | 0.351 - 2.100 |
More Stats
| Market Cap | 61.75M |
| Enterprise Value | 86.14M |
| Earnings Date (est) | Mar 11, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 143.52M |
| Float | 97.27M |
| EPS (basic) | -0.33 |
| EPS (diluted) | -0.34 |
| FCF / Share | -0.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 2.36M |
| Short Ratio | 1.28 |
| Short % of Float | 2.42% |
| Beta | 1.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 1.72 |
| PB Ratio | 8.20 |
| Revenue | 35.94M |
| Operating Income | -33.54M |
| Net Income | -40.34M |
| Free Cash Flow | -31.99M |
| Net Cash | -24.38M |
| Net Cash / Share | -0.17 |
| Gross Margin | 6.43% |
| Operating Margin | -93.32% |
| Profit Margin | -112.20% |
| FCF Margin | -89.02% |
| ROA | -26.42% |
| ROE | -342.81% |
| ROIC | -52.00% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.37 | 2.96 | 7.54 | 1.62 | 26.57 | 3.47 | 2.14 | 3.53 | 4.97 | 23.05 |
| Revenue Growth | 587.77% | -60.72% | 365.37% | -93.9% | 664.9% | 62.06% | -39.22% | -28.98% | -78.46% | - |
| Gross Profit | 17.68 | 2.96 | 7.54 | 1.62 | 26.57 | 3.47 | 2.14 | 3.53 | 4.97 | 23.05 |
| Operating Income | -47.86 | -26.27 | -18.58 | -21.77 | 6.42 | -13.49 | -12.03 | -25.21 | -10.00 | 9.09 |
| Net Income | -56.79 | -53.17 | -18.49 | -21.55 | 6.35 | -13.36 | -11.90 | -24.84 | -8.63 | 8.75 |
| Shares Outstanding | 104 | 46.23 | 35.34 | 31.62 | 29.38 | 27.44 | 23.04 | 20.79 | 19.49 | 18.41 |
| Earnings Per Share | -0.54 | -1.15 | -0.52 | -0.68 | 0.21 | -0.49 | -0.52 | -1.19 | -0.44 | 0.46 |
| Operating Cash Flow | -56.70 | -21.91 | -20.49 | -16.32 | 10.30 | -10.67 | -8.75 | -9.00 | -3.17 | 9.90 |
| Capital Expenditures | -0.21 | -0.11 | -0.11 | -0.11 | -0.16 | -0.17 | -0.07 | -0.41 | -0.13 | -0.02 |
| Free Cash Flow | -56.91 | -22.02 | -20.60 | -16.43 | 10.14 | -10.84 | -8.81 | -9.41 | -3.30 | 9.88 |
| Cash & Equivalents | 22.36 | 38.93 | 17.05 | 29.14 | 28.69 | 18.43 | 10.27 | 14.57 | 24.13 | 17.57 |
| Total Debt | 50.12 | 17.31 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | -27.76 | 21.62 | 17.05 | 29.14 | 28.69 | 18.43 | 10.27 | 14.57 | 24.13 | 17.57 |
| Assets | 72.97 | 71.67 | 18.68 | 31.62 | 32.37 | 22.67 | 16.25 | 20.60 | 47.11 | 43.01 |
| Liabilities | 64.64 | 59.98 | 5.34 | 10.74 | 9.00 | 7.75 | 8.55 | 6.96 | 9.68 | 9.97 |
| Book Value | 8.33 | 11.69 | 13.34 | 20.88 | 23.37 | 14.92 | 7.70 | 13.64 | 37.43 | 33.04 |
Company Profile
Company Details
| Full Name | EyePoint Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 84 |
| CEO | Nancy Sue Lurker |
Stock Information
| Ticker Symbol | EYPT |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: EYPT |
| IPO Date | January 27, 2005 |
Description
EyePoint Pharmaceuticals, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.